1 – 10 of 49
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Pain, depression and anxiety in people with haemophilia from three Nordic countries : Cross-sectional survey data from the MIND study
(
- Contribution to journal › Article
-
Mark
Long-term joint outcomes in adolescents with moderate or severe haemophilia A
(
- Contribution to journal › Article
-
Mark
Alternative payment models for durable and potentially curative therapies : The case of gene therapy for haemophilia A
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?
(
- Contribution to journal › Article
-
Mark
Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins : Real-world experience in the Nordic countries
(
- Contribution to journal › Article
- 2021
-
Mark
Validation of factor VIII activity for monitoring standard and extended half-life products and correlation to thrombin generation assays
(
- Contribution to journal › Article
-
Mark
Real-world prophylactic usage of recombinant factor VIII Fc in Sweden : A report from the Swedish national registry for bleeding disorders
(
- Contribution to journal › Letter
-
Mark
Optimising prophylaxis in haemophilia A : The ups and downs of treatment
(
- Contribution to journal › Scientific review
- 2020
-
Mark
Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B
(
- Contribution to journal › Scientific review
- 2019
-
Mark
Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A : Combined analysis of three studies
(
- Contribution to journal › Article